Invention Grant
- Patent Title: Therapeutic cancer vaccines derived from a novel dendritic cell line
-
Application No.: US14648210Application Date: 2013-12-10
-
Publication No.: US10064923B2Publication Date: 2018-09-04
- Inventor: Sandra Van Wetering , Adriana Marie Kruisbeek
- Applicant: DCPRIME B.V.
- Applicant Address: NL Leiden
- Assignee: DCPRIME B.V.
- Current Assignee: DCPRIME B.V.
- Current Assignee Address: NL Leiden
- Agency: Patent Law Works LLP
- Priority: EP12196496 20121211
- International Application: PCT/EP2013/076067 WO 20131210
- International Announcement: WO2014/090795 WO 20140619
- Main IPC: C12N5/00
- IPC: C12N5/00 ; C12N5/02 ; A61K39/00 ; C12N5/0784 ; A61K35/15
Abstract:
The invention is in the field of medical sciences. It provides means and methods for the treatment of cancer. More in particular, it provides cells and cell lines that can be developed into fully functional dendritic cells. These cells endogenously express cancer-specific antigens, which makes them particularly suited for the treatment of different kinds of cancer. More in particular, the invention relates to a precursor cell line for dendritic cells called DC-One as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012.
Public/Granted literature
- US20150297698A1 THERAPEUTIC CANCER VACCINES DERIVED FROM A NOVEL DENDRITIC CELL LINE Public/Granted day:2015-10-22
Information query
